Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

(2010) Charles J. Ryan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

(2009) G. Attard et al.   CANCER RESEARCH

Characterization of circulating tumor cells by fluorescence in situ hybridization

(2009) Joost F. Swennenhuis et al.   CYTOMETRY PART A

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

(2009) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

(2009) Howard I Scher et al.   LANCET ONCOLOGY

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

(2008) D. Olmos et al.   ANNALS OF ONCOLOGY

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer

(2008) Sunita R. Setlur et al.   JNCI-Journal of the National Cancer Institute